Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

MLA

Poplin, Elizabeth, et al. “Randomized, Multicenter, Phase II Study of CO-101 versus Gemcitabine in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of HENT1 in Gemcitabine or CO-101 Sensitivity.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 31, no. 35, Dec. 2013, pp. 4453–61. EBSCOhost, https://doi.org/10.1200/JCO.2013.51.0826.

APA

Poplin, E., Wasan, H., Rolfe, L., Raponi, M., Ikdahl, T., Bondarenko, I., Davidenko, I., Bondar, V., Garin, A., Boeck, S., Ormanns, S., Heinemann, V., Bassi, C., Evans, T. R. J., Andersson, R., Hahn, H., Picozzi, V., Dicker, A., Mann, E., … Allen, A. (2013). Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31(35), 4453–4461. https://doi.org/10.1200/JCO.2013.51.0826

Chicago

Poplin, Elizabeth, Harpreet Wasan, Lindsey Rolfe, Mitch Raponi, Tone Ikdahl, Ihor Bondarenko, Irina Davidenko, et al. 2013. “Randomized, Multicenter, Phase II Study of CO-101 versus Gemcitabine in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of HENT1 in Gemcitabine or CO-101 Sensitivity.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31 (35): 4453–61. doi:10.1200/JCO.2013.51.0826.